CLEARY, DARRYL G.,REYNOLDS, CHARLES J.,BERREY, MIRIAM MICHELLE,HINDES, ROBERT G.,SYMONDS, WILLIAM T.,RAY, ADRIAN S.,MO, HONGMEI,HEBNER, CHRISTY M.,OLIYAI, REZA,ZIA, VAHID,STEFANIDIS, DIMITRIOS,PAKDAMA
申请号：
CA2856529
公开号：
CA2856529C
申请日:
2012.11.27
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
